Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Unicycive Therapeutics (UNCY) and maintains a $3 price target.
April 15, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Unicycive Therapeutics with a $3 price target.
The reiteration of a Speculative Buy rating and a maintained price target of $3 by a Benchmark analyst could positively influence investor sentiment towards UNCY, potentially driving short-term interest and upward price movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100